Edition:
India

Novo Nordisk A/S (NVO.N)

NVO.N on New York Stock Exchange

37.36USD
26 Apr 2017
Change (% chg)

$0.28 (+0.76%)
Prev Close
$37.08
Open
$37.30
Day's High
$37.53
Day's Low
$37.28
Volume
571,507
Avg. Vol
505,735
52-wk High
$57.42
52-wk Low
$30.90

NVO.N

Chart for NVO.N

About

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity... (more)

Overall

Beta: 0.74
Market Cap(Mil.): $73,119.88
Shares Outstanding(Mil.): 1,962.56
Dividend: 0.67
Yield (%): 3.62

Financials

  NVO.N Industry Sector
P/E (TTM): 16.97 29.34 30.35
EPS (TTM): 2.20 -- --
ROI: 75.08 13.84 13.36
ROE: 82.23 14.77 14.50

BRIEF-Xoma receieves notice to terminate license agreement from Novo Nordisk

* Xoma -on april 20, 2017 co received notice from Novo Nordisk a/s, relating to termination of exclusive license agreement with co due to strategic and business reasons

22 Apr 2017

BRIEF-Novo's once-weekly semaglutide shows consistent bloodglucose reductions

* Says once-weekly semaglutide demonstrated consistent bloodglucose reductions and weight loss regardless of background oral antidiabetic treatment

03 Apr 2017

BRIEF-Novo Nordisk resubmits new drug application for fast-acting insulin aspart in the U.S

* Says has resubmitted the new drug application (NDA) for fast-acting insulin aspart as a class II re-submission to the United States Food and Drug Administration (FDA)

29 Mar 2017

BRIEF-Novo Nordisk launches Fiasp-drug in Canada

* Says Fiasp, a new, fast-acting mealtime insulin for the treatmentof diabetes in adults, has been launched in Canada on Monday Further company coverage: (Reporting by Stine Jacobsen)

27 Mar 2017

EMA panel backs Novo Nordisk's hemophilia B drug

A panel of the European Medicines Agency said it recommended granting marketing approval to Danish drugmaker Novo Nordisk's hemophilia B drug.

24 Mar 2017

UPDATE 1-EMA panel backs Novo Nordisk's haemophilia B drug

March 24 A panel of the European Medicines Agency said it recommended granting marketing approval to Danish drugmaker Novo Nordisk's haemophilia B drug.

24 Mar 2017

EMA panel backs Novo Nordisk's haemophilia B drug

March 24 A panel of the European Medicines Agency said it recommended granting marketing approval to Danish drugmaker Novo Nordisk's haemophilia B drug.

24 Mar 2017

BRIEF-EU recommends approval of Novo Nordisk's haemophilia drug

* Recommends approval of Novo Nordisk's Nonacog Beta Pegol drug for treatment of haemophilia

24 Mar 2017

BRIEF-Novo Nordisk gets positive opinion for label update in EU for Tresiba

* The Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), has issued a positive opinion, recommending an update of the label for Tresiba (insulin degludec) to include data from the SWITCH 1 and 2 clinical trials

24 Mar 2017

BRIEF-Denmark's Novo Nordisk will not turn into big M&A machine-CEO

March 23 The CEO of Novo Nordisk's, the world's biggest diabetes company, made the following comments at the firm's annual general meeting on Thursday:

23 Mar 2017

More From Around the Web

Competitors

  Price Chg
Sanofi SA (SASY.PA) €85.65 --
Eli Lilly and Co (LLY.N) $80.96 -0.24

Earnings vs. Estimates